Diplomat Pharmacy, Inc. (DPLO) Downgraded by BidaskClub to Sell

BidaskClub lowered shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) from a hold rating to a sell rating in a report released on Monday, July 31st.

Several other research firms have also recently issued reports on DPLO. Mizuho increased their target price on Diplomat Pharmacy from $17.00 to $19.00 and gave the stock a neutral rating in a research report on Tuesday, May 16th. Leerink Swann reiterated a market perform rating and set a $18.00 target price (up previously from $16.00) on shares of Diplomat Pharmacy in a research report on Wednesday, May 17th. Barclays PLC set a $20.00 target price on Diplomat Pharmacy and gave the stock a buy rating in a research report on Tuesday, May 9th. Zacks Investment Research cut Diplomat Pharmacy from a hold rating to a sell rating in a research report on Monday, July 17th. Finally, Needham & Company LLC initiated coverage on Diplomat Pharmacy in a research report on Friday, July 21st. They set a buy rating and a $19.75 target price for the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $17.89.

Shares of Diplomat Pharmacy (DPLO) traded up 1.63% on Monday, reaching $16.20. 733,956 shares of the company were exchanged. The company’s 50-day moving average price is $15.43 and its 200 day moving average price is $15.74. Diplomat Pharmacy has a 12 month low of $12.25 and a 12 month high of $34.80. The company has a market cap of $1.10 billion, a price-to-earnings ratio of 88.52 and a beta of 0.66.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, August 7th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. During the same quarter last year, the company earned $0.23 earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities research analysts expect that Diplomat Pharmacy will post $0.75 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Diplomat Pharmacy, Inc. (DPLO) Downgraded by BidaskClub to Sell” was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/13/bidaskclub-lowers-diplomat-pharmacy-inc-dplo-to-sell-updated.html.

A number of institutional investors have recently added to or reduced their stakes in DPLO. JPMorgan Chase & Co. boosted its position in Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after buying an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Diplomat Pharmacy by 46.7% in the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after buying an additional 2,794 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in Diplomat Pharmacy by 13.8% in the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after buying an additional 1,073 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan boosted its position in Diplomat Pharmacy by 4.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after buying an additional 480 shares in the last quarter. Institutional investors and hedge funds own 72.02% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply